22 May 2026

62 days to PCAC. No new vacancy appointments in 19+ weeks. Historian: reference class for advisory-committee vacancy dynamics stable — 4 of 12 seated, no chair. Quorum risk identified yesterday remains live as dual-direction signal (no quorum = no recommendation = forecast TRUE; batch-fill = pro-access = forecast FALSE). Skeptic: Kennedy's inaction is accumulating but not yet dispositive. The PCAC was formally renewed to 2028 (Federal Register April 30), confirming institutional intent. Bayesian: prior 0.55, posterior 0.55. No new directional evidence. Augur: TRIUMPH-1 readout creates a fresh wave of mainstream GLP-1 coverage that could collaterally raise awareness of the July 23 PCAC meeting — second-order and not probability-moving.

Same quorum and institutional-capacity constraints. No USP monograph progress for any of four tracked peptides. Oral presentation notification deadline June 30 is the next signal-rich window — industry coalition presentations will reveal the depth of organized support.

No new launch announcement 11 days post-Q1 earnings. Historian: Hims M&A-to-launch cadence — California peptide facility acquired Feb 2025, now month 15. Consumer health platforms typically launch acquired-capability products within 12–24 months of M&A. Within window but timing distribution shifting to H2. Skeptic: Hims expanding into diagnostics and Canada divides corporate attention. Post-Q1 silence is consistent with waiting for PCAC regulatory cover rather than pre-PCAC boldness. Bayesian: TRIUMPH-1 doesn't directly impact peptide launch timing. Holding 0.84. Augur: if retatrutide's dysesthesia makes the branded GLP-1 pipeline less clean, peptides become a diversification hedge for Hims — but this is speculative.

No new adverse events. No new top-5 outlet features. Historian: pharmacovigilance-to-media pipeline remains in late build-phase (ProPublica, ECRI, ISMP, PBS, academic papers positioned). Base rate: once institutional actors have published preliminary safety analyses, downstream top-5 outlet features follow within 3–12 months in ~60% of cases. Skeptic: 10 months remain on 12-month horizon but trigger event (named victim, death, class action) still absent. Bayesian: prior 0.70, posterior 0.70. BSR Intelligence peptide industry briefing (March–May 2026) confirms counterfeit and contamination risk at elevated baseline. No new inflection. Augur: TRIUMPH-1 dysesthesia coverage creates a "side effects of these drugs" media frame that could spillover to peptide safety discourse. Template-adjacent, not trigger.

40 days to July 1 launch. CMS operational silence continues — spring 2026 guidance still undelivered. Historian: government-program launch silence at T-40 weakly correlates with slow-ramp per Medicare Part D initial rollout reference class. Skeptic: structural friction unchanged ($50 copay not toward OOP cap, PA mandatory, narrow drug list). Bayesian: prior 0.72, posterior 0.72. TRIUMPH-1 retatrutide is not Bridge-eligible (not yet approved). No enrollment data. Augur: TRIUMPH-1 creates a fresh GLP-1 news cycle that could raise incidental Bridge awareness, but this is second-order.

40 days to launch.

No new peptide DTC affiliate programs surfaced. TRIUMPH-1 deepens the branded GLP-1 pipeline (Foundayo live, retatrutide NDA expected late 2026, CagriSema PDUFA Q4 2026). Each new branded GLP-1 reinforces the CPA dominance ($260+ vs $8–40 peptide). Math unchanged.

compound-peptide-property-live: holds 0.85, flagged. Seventh consecutive day flagged for formal resolution. Per operator clarification 2026-05-15, the broader portfolio-ship thesis is satisfied (4 live properties in 75 days). Recommend operator resolve TRUE and retire from daily re-evaluation.